Literature DB >> 32459538

IL-1R (Interleukin-1 Receptor) Signaling and Attenuated Hepatic CYP (Cytochrome P450) 2C Expression: Explanation for Higher Rate of Clopidogrel Resistance in Patients With Diabetes Mellitus?

Rolf P Kreutz1.   

Abstract

Entities:  

Keywords:  Editorials clopidogrel; humans; interleukin; isoenzymes; metabolic syndrome

Mesh：

Substances：

Year:  2020        PMID： 32459538      PMCID： PMC7263358          DOI： 10.1161/ATVBAHA.120.314446

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  16 in total

1.  First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

Authors:  Udaya S Tantry; Kevin P Bliden; Cheryl Wei; Robert F Storey; Martin Armstrong; Kathleen Butler; Paul A Gurbel
Journal:  Circ Cardiovasc Genet       Date:  2010-11-15

2.  Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans.

Authors:  Lea M Beaulieu; Elaine Lin; Eric Mick; Milka Koupenova; Ellen O Weinberg; Carolyn D Kramer; Caroline A Genco; Kahraman Tanriverdi; Martin G Larson; Emelia J Benjamin; Jane E Freedman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-01-23       Impact factor: 8.311

3.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

4.  Clopidogrel Pharmacogenetics.

Authors:  Naveen L Pereira; Charanjit S Rihal; Derek Y F So; Yves Rosenberg; Ryan J Lennon; Verghese Mathew; Shaun G Goodman; Richard M Weinshilboum; Liewei Wang; Linnea M Baudhuin; Amir Lerman; Ahmed Hasan; Erin Iturriaga; Yi-Ping Fu; Nancy Geller; Kent Bailey; Michael E Farkouh
Journal:  Circ Cardiovasc Interv       Date:  2019-04       Impact factor: 6.546

5.  Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.

Authors:  Matthew J Price; Keshav R Nayak; Colin M Barker; David E Kandzari; Paul S Teirstein
Journal:  Am J Cardiol       Date:  2009-04-01       Impact factor: 2.778

6.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

7.  Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.

Authors:  H J Bouman; E Parlak; J W van Werkum; N J Breet; H ten Cate; C M Hackeng; J M ten Berg; D Taubert
Journal:  J Thromb Haemost       Date:  2009-12-21       Impact factor: 5.824

8.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Authors:  Larisa H Cavallari; Craig R Lee; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Julio D Duarte; Deepak Voora; Stephen E Kimmel; Caitrin W McDonough; Yan Gong; Chintan V Dave; Victoria M Pratt; Tameka D Alestock; R David Anderson; Jorge Alsip; Amer K Ardati; Brigitta C Brott; Lawrence Brown; Supatat Chumnumwat; Michael J Clare-Salzler; James C Coons; Joshua C Denny; Chrisly Dillon; Amanda R Elsey; Issam S Hamadeh; Shuko Harada; William B Hillegass; Lindsay Hines; Richard B Horenstein; Lucius A Howell; Linda J B Jeng; Mark D Kelemen; Yee Ming Lee; Oyunbileg Magvanjav; May Montasser; David R Nelson; Edith A Nutescu; Devon C Nwaba; Ruth E Pakyz; Kathleen Palmer; Josh F Peterson; Toni I Pollin; Alison H Quinn; Shawn W Robinson; Jamie Schub; Todd C Skaar; D Max Smith; Vindhya B Sriramoju; Petr Starostik; Tomasz P Stys; James M Stevenson; Nicholas Varunok; Mark R Vesely; Dyson T Wake; Karen E Weck; Kristin W Weitzel; Russell A Wilke; James Willig; Richard Y Zhao; Rolf P Kreutz; George A Stouffer; Philip E Empey; Nita A Limdi; Alan R Shuldiner; Almut G Winterstein; Julie A Johnson
Journal:  JACC Cardiovasc Interv       Date:  2017-11-01       Impact factor: 11.195

9.  The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.

Authors:  S Neergaard-Petersen; A-M Hvas; S D Kristensen; E L Grove; S B Larsen; F Phoenix; Z Kurdee; P J Grant; R A Ajjan
Journal:  Thromb Haemost       Date:  2014-09-04       Impact factor: 5.249

10.  Fibrin Clot Strength in Patients with Diabetes Mellitus Measured by Thrombelastography.

Authors:  Benjamin T Maatman; Glen Schmeisser; Rolf P Kreutz
Journal:  J Diabetes Res       Date:  2018-02-04       Impact factor: 4.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.